EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Reliability of early stage symptoms/clinical findings of osteonecrosis of the jaw: Japanese Osteoporosis Intervention Trial-05 (JOINT-05)

Akira Taguchi, Shiro Tanaka, Tatsuro Ozaki, Koshiro Arai, Satoshi Mori, Hiroaki Ohta, Hiroshi Hagino, Sakae Tanaka, Masataka Shiraki, Toshitaka Nakamura, Satoshi Soen, Adequate Treatment of Osteoporosis (A-TOP) Research Group

Journal of Bone and Mineral Metabolism · 2023

DOI: 10.1007/s00774-023-01466-3 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Bone and Mineral Metabolism, 2023. Verfasst von Akira Taguchi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Radiology, School of Dentistry, Matsumoto Dental University, 1780 Hirooka Gobara, Shiojiri, Nagano, 399-0781, Ja…. Hauptthemen laut MEDLINE: Bisphosphonate-Associated Osteonecrosis of the Jaw, Bone Density Conservation Agents, Osteoporosis, Tooth Mobility. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science London, Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: To investigate the differences in the incidence rates of suspected stage 0/1 osteonecrosis of the jaw (ONJ) and incidence risk of relevant clinical findings of suspected stage 0 ONJ between patients treated with sequential therapy comprising weekly teriparatide for 72 weeks followed by alendronate for 48 weeks vs. those who received monotherapy with alendronate for 120 weeks. MATERIALS AND METHODS: Suspected stage 0/1 ONJ was defined by non-specific symptoms. Tooth mobility and periodontal symptoms (gingival bleeding, swelling, and/or pain) were selected as clinical findings of suspected stage 0 ONJ. Poisson regression models were applied to calculate the incidence rate ratios of suspected stage 0/1 between the teriparatide group (TG) and alendronate group (AG). Generalized linear models were used to calculate the risk ratios of clinical findings between groups. RESULTS: Two hundred and sixty-one participants in the TG and 344 in the AG answered a structured questionnaire on oral health and were included in this study. There were no significant differences between the groups in the incidence rate of suspected stage 0/1 ONJ at both 72 and 120 weeks. The risk ratio of the TG to AG for tooth mobility was 0.34 (95% confidence interval [CI] 0.13-0.88, p = 0.02) at 72 weeks and 0.90 (95% CI 0.40-2.03, p = 0.83) at 120 weeks. The incidence rate of tooth mobility related to periodontal symptoms decreased in the TG and increased in the AG during the study. CONCLUSION: Tooth mobility accompanied by clinical periodontal symptoms may be a useful early sign of stage 0 ONJ.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bisphosphonate-Associated Osteonecrosis of the JawBone Density Conservation AgentsOsteoporosisTooth MobilityHumansAlendronateDiphosphonatesEast Asian PeopleReproducibility of ResultsTeriparatide

Stichwörter der Autor:innen

AlendronateOsteonecrosis of the jawOsteoporosisTeriparatideTooth mobility

Substanzen

AlendronateBone Density Conservation AgentsDiphosphonatesTeriparatide

Autor:innen und Institutionen

  • Department of Oral and Maxillofacial Radiology, School of Dentistry, Matsumoto Dental University, 1780 Hirooka Gobara, Shiojiri, Nagano, 399-0781, Japan. akira.taguchi@mdu.ac.jp.
  • Department of Hard Tissue Research, Graduate School of Oral Medicine, Matsumoto Dental University, 1780 Gobara, Hirooka, Shiojiri, Nagano, 399-0781, Japan. akira.taguchi@mdu.ac.jp.
  • Department of Clinical Biostatistics, Graduate School of Medicine, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan.
  • Clinical Biostatistics Course, Graduate School of Medicine, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan.
  • Bone and Joint Surgery, Seirei Hamamatsu General Hospital, Shizuoka, 430-8558, Japan.
  • Kawasaki Medical School General Medical Center, 2-6-1 Nakayama-shita, Kita-ku, Okayama, 700-8505, Japan.

Förderung

  • Japan Society for the Promotion of Science London
  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development
  • Public Health Research Foundation

Zitieren

APA

Taguchi, A., Tanaka, S., Ozaki, T., Arai, K., Mori, S., Ohta, H., Hagino, H., Tanaka, S., Shiraki, M., Nakamura, T., Soen, S., & Adequate Treatment of Osteoporosis (A-TOP) Research Group (2023). Reliability of early stage symptoms/clinical findings of osteonecrosis of the jaw: Japanese Osteoporosis Intervention Trial-05 (JOINT-05). Journal of Bone and Mineral Metabolism. https://doi.org/10.1007/s00774-023-01466-3

Vancouver

Taguchi A, Tanaka S, Ozaki T, Arai K, Mori S, Ohta H, et al. Reliability of early stage symptoms/clinical findings of osteonecrosis of the jaw: Japanese Osteoporosis Intervention Trial-05 (JOINT-05). Journal of Bone and Mineral Metabolism. 2023. doi:10.1007/s00774-023-01466-3

BibTeX
@article{Taguchi2023,
  author = {Taguchi, Akira and Tanaka, Shiro and Ozaki, Tatsuro and Arai, Koshiro and Mori, Satoshi and Ohta, Hiroaki and Hagino, Hiroshi and Tanaka, Sakae and Shiraki, Masataka and Nakamura, Toshitaka and Soen, Satoshi and Adequate Treatment of Osteoporosis (A-TOP) Research Group, Adequate Treatment of Osteoporosis (A-TOP) Research Group},
  title = {Reliability of early stage symptoms/clinical findings of osteonecrosis of the jaw: Japanese Osteoporosis Intervention Trial-05 (JOINT-05)},
  journal = {Journal of Bone and Mineral Metabolism},
  year = {2023},
  doi = {10.1007/s00774-023-01466-3}
}
Kostenlos starten →